Heron Therapeutics, Inc. (HRTX)
Automate Your Wheel Strategy on HRTX
With Tiblio's Option Bot, you can configure your own wheel strategy including HRTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HRTX
- Rev/Share 1.0292
- Book/Share -0.1854
- PB -11.3824
- Debt/Equity -6.2298
- CurrentRatio 2.4034
- ROIC -0.0239
- MktCap 321910040.0
- FreeCF/Share -0.1544
- PFCF -13.5838
- PE -41.601
- Debt/Assets 0.7519
- DivYield 0
- ROE 0.2224
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | HRTX | H.C. Wainwright | -- | Buy | -- | $6 | June 9, 2025 |
News
Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Positive
HRTX's Q1'25 earnings highlight Cinvanti as the top earner, but Zynrelef shows strong growth potential, with 60% growth in net sales vs Q1'24. HRTX reported net income of $2.6M and raised its full-year adjusted EBITDA guidance, but potential equity offerings to manage debt remain a risk. HRTX's CEO speaks of Zynrelef's multi-hundred-million-dollar potential, although it may take several more quarters of sales growth to convince the market of that potential.
Read More
Heron Therapeutics, Inc. (HRTX) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Melissa Jarel - Executive Director, Legal Craig Collard - Chief Executive Officer Ira Duarte - Executive Vice President, Chief Financial Officer Conference Call Participants Yuxi Dong - Jefferies Serge Belanger - Needham & Company Carl Byrnes - Northland Capital Markets Operator Good day, and thank you for standing by. Welcome to the Heron Therapeutics Q1 2025 Conference Call.
Read More
Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Heron Therapeutics (HRTX) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.02 per share a year ago.
Read More
Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates
Published: May 06, 2025 by: PRNewsWire
Sentiment: Neutral
Generated Q1 2025 Net Revenue of $38.9 million Delivered record Q1 2025 Adjusted EBITDA of $6.2 million Reached settlement with Mylan Pharmaceuticals, Inc., regarding the parties' CINVANTI ® and APONVIE ® patent litigations, including an agreed market entry date of June 1, 2032 Adjusted EBITDA guidance raised to a range of $4 - $12M for full year 2025 CARY, N.C. , May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2025, and highlighted recent corporate updates.
Read More
Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations
Published: May 06, 2025 by: PRNewsWire
Sentiment: Neutral
— Company Grants Mylan a License to Market Generic CINVANTI® and APONVIE® Beginning in June 2032 — CARY, N.C. , May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company entered into a settlement agreement with Mylan Pharmaceuticals, Inc. ("Mylan"), a Viatris Inc. company, to resolve the ongoing patent litigations between the parties in the U.S. District Court for the District of Delaware related to CINVANTI® (aprepitant) injectable emulsion and APONVIE® (aprepitant) injectable emulsion.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: April 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
Best Momentum Stocks to Buy for April 22nd
Published: April 22, 2025 by: Zacks Investment Research
Sentiment: Positive
DPMLF, HRTX and FOX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 22, 2025.
Read More
Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates
Published: February 27, 2025 by: PRNewsWire
Sentiment: Neutral
Achieved Q4 2024 GAAP Net Income of $3.6 million Generated full-year 2024 Net Revenue of $144.2 million, up 14% year-over-year Delivered full-year 2024 adjusted EBITDA of $8.6 million Generated ZYNRELEF® Q4 2024 Net Revenue of $8.5 million and launched the ZYNRELEF Vial Access Needle ("VAN") in December 2024 U.S. District Court ruled in favor of Heron in patent lawsuit against Fresenius Kabi USA, LLC, and upheld the validity of CINVANTI® patents which expire in 2035 CARY, N.C. , Feb. 27, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results …
Read More
About Heron Therapeutics, Inc. (HRTX)
- IPO Date 1987-08-26
- Website https://www.herontx.com
- Industry Biotechnology
- CEO Mr. Craig Alexander Collard
- Employees 122